ArticleBiomedical engineering online2025
Decellularized bone extracellular matrix embedded with PLGA-linezolid microparticles for infected bone regeneration.
Article in Biomedical engineering online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDual-functional antibacterial and osteogenic substitutes are advanced tools for treating bone infections while facilitating bone regeneration. These systems incorporate drug delivery mechanisms that allow for the local release of antibiotics and increased treatment efficacy. Decellularized bone extracellular matrix (dECM) offers key advantages for bone xenografts and local drug delivery due to its biocompatibility and low immunogenicity. This study developed a novel scaffold by loading linezolid-poly (lactic-co-glycolic acid) (PLGA-Lin) microparticles onto dECM derived from bovine tibia. The antibacterial activity, cytocompatibility, and osteoconductive properties of the resulting Lin-PLGA/dECM scaffold were assessed in vitro.
resultsThe results revealed that the dECM had a porous structure and the Lin-PLGA microparticles infiltrated the scaffold. None of the dECM, PLGA/dECM, or Lin-PLGA/dECM scaffolds had toxic effects on adipose tissue-derived mesenchymal stem cells (ADSCs), while the inhibitory effect of Lin-PLGA/dECM on the Staphylococcus aureus strain was significant. All scaffolds-dECM, PLGA/dECM, and Lin-PLGA/dECM-promoted the bone differentiation of ADSCs, as confirmed by alkaline phosphatase (ALP) and calcium content assays, as well as by the expression of the Runt-related transcription factor 2 (Runx2), osteopontin, osteocalcin, and collagen Iα genes.
conclusionsThe Lin-PLGA/dECM scaffold developed in this study can be considered a biocompatible bone xenograft substitute, as it possesses excellent antibacterial properties and substantial osteogenic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.